BioDelivery Sciences price target raised to $13 from $9 at Ladenburg Ladenburg raised its price target on shares of BioDelivery Sciences to $13 from $9 following positive top-line data for one of its BEMA buprenorphine Phase III trials. Ladenburg believes these results portend a high probability for positive results from another ongoing Phase 3 study of the drug in another set of patients and the firm maintains a Buy rating on shares.
Summer Street still feels Endo could acquire BioDelivery Sciences Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.